Home/Pipeline/Oral Norovirus Vaccine

Oral Norovirus Vaccine

Norovirus Gastroenteritis

Phase 2Active

Key Facts

Indication
Norovirus Gastroenteritis
Phase
Phase 2
Status
Active
Company

About Vaxart

Vaxart's mission is to transform global health by developing oral recombinant pill vaccines that generate mucosal and systemic immunity. The company's core strategy leverages its proprietary delivery platform to create vaccines that are easier to administer, do not require cold-chain logistics, and could potentially reduce transmission of viruses. While still in clinical development, Vaxart aims to address significant unmet needs in infectious diseases with a more accessible and potentially more effective vaccine format.

View full company profile